ASTRAZENECA
ASTRAZENECA is a French société par actions simplifiée (SAS) registered with the Registre du commerce et des sociétés (RCS) of Nanterre under SIREN 558 201 075. Its registered office, which is also its head establishment (SIRET 558 201 075 00071), is at Tour Carpe Diem, 31 place des Corolles, 92400 Courbevoie. Its administrative status in the Sirene register is active. It should not be confused with AstraZeneca PLC, the UK-listed company.
The activity recorded in the register for ASTRAZENECA is the manufacture and sale of pharmaceutical products, with the NAF code 21.20Z (manufacture of pharmaceutical preparations). Its French VAT number is FR87558201075. INSEE classes it as a large enterprise (GE). Its 2024 headcount band is 1,000 to 1,999 employees. The company publishes the French website astrazeneca.fr. The site’s legal notice names this company, with its RCS Nanterre number and a share capital of EUR 61,148,640, as the publisher. The notice also places its content under the responsibility of the company’s pharmacien responsable.
Sirene records a creation date of 1 January 1973. Sirene often uses a first-of-January date for older records, so this is not confirmed as the date of incorporation. The head establishment at Courbevoie was opened on 22 February 2016. A BODACC notice of 29 February 2016 published the transfer of the registered office there from Rueil-Malmaison.
The figures below come from the company’s own (non-consolidated) annual accounts, as published in the INPI/BCE financial-ratios open dataset. For the year to 31 December 2025, ASTRAZENECA SAS reported revenue of EUR 1,211.5 million and net profit of EUR 25.2 million. For 2024 the figures were EUR 999.2 million and EUR 37.8 million, and for 2023 EUR 880.6 million and EUR 29.0 million. Its operating result before depreciation (EBE) was negative in each of those three years. Accounts for the 2025 financial year were filed, according to a BODACC notice of 14 July 2026. As a separate figure, AstraZeneca PLC’s 2025 annual report gives total revenue of USD 1,408 million for France. That is a group figure covering all of the group’s French companies, not this company alone.
Business transfers published in BODACC include the purchase of a business (fonds) from Bristol-Myers Squibb, effective 1 April 2014 (notice of 2 May 2014). On 10 July 2022 BODACC also published the sale of a business previously held at ASTRAZENECA’s Courbevoie address to Alexion Pharma France. That sale was effective 1 July 2022. A controlled BODACC search found no insolvency-proceedings or strike-off notice for this SIREN.
Sources
- Recherche d’entreprises API (INSEE Sirene / RNE data), SIREN 558201075: https://recherche-entreprises.api.gouv.fr/search?q=558201075 (record updated 2026-10-14; retrieved 2026-10-15)
- BODACC, all 40 notices for RCS 558 201 075: https://bodacc-datadila.opendatasoft.com/explore/dataset/annonces-commerciales/ (notices of 2014-05-02, 2016-02-29, 2022-07-10 and 2026-07-14; retrieved 2026-10-15). Control: the same query returns two insolvency-proceedings notices for ORPEA (SIREN 401 251 566).
- INPI/BCE financial-ratios open dataset (ratios_inpi_bce), SIREN 558201075, individual accounts: https://data.economie.gouv.fr/explore/dataset/ratios_inpi_bce/ (financial years 2023 to 2025; retrieved 2026-10-15)
- astrazeneca.fr legal notice: https://www.astrazeneca.fr/mentions-legales.html (retrieved 2026-10-15)
- AstraZeneca PLC, Annual Report on Form 20-F for 2025, geographic-areas table (printed page F-21): https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm (filed 2026-02-24; retrieved 2026-10-15)
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
1
Shareholders of ASTRAZENECA
No French public register names the shareholders of ASTRAZENECA (SIREN 558 201 075), a société par actions simplifiée. The ownership figure available comes from the parent group’s filing. AstraZeneca PLC’s Annual Report on Form 20-F for 2025, filed on 24 February 2026, lists “AstraZeneca SAS” at Tour Carpe Diem, 31 place des Corolles, Courbevoie. It appears among the wholly owned subsidiaries, with a group interest of 100% at 31 December 2025. The note states that, unless otherwise stated, the shares are ordinary shares held indirectly by AstraZeneca PLC. No footnote marks this company as directly held. The filing therefore establishes a 100% indirect group interest. It does not name the immediate shareholder or the intermediate companies.
The shareholder table supplied with this profile shows a natural person as the 100% holder. No filing reviewed supports that holding, and it conflicts with the group’s own disclosure above. It should not be relied on.
A merger is relevant to the shareholding. A BODACC notice of 1 July 2021 published the draft merger by which ASTRAZENECA absorbed ASTRA ZENECA HOLDING FRANCE (SIREN 399 324 011). New shares were to be issued to the absorbed company’s sole shareholder. That shareholder is not named in the notice.
Ultimate beneficial ownership
AstraZeneca PLC is a listed company; its shares trade under the symbol AZN, according to its 20-F. That filing reports ASTRAZENECA SAS as 100% owned by the group, held indirectly. No natural person is identified as a beneficial owner of ASTRAZENECA in any public source reviewed.
Data availability
Availability: Partial (group-level percentage only). French registers do not publish the shareholders of an SAS. Since November 2022, the French register of beneficial owners (RBE) is no longer open to the public. The immediate shareholder and the share capital split are therefore not public. The latest share capital figure published in BODACC (notice of 12 October 2021) and on the company’s website is EUR 61,148,640.
Sources
- AstraZeneca PLC, Annual Report on Form 20-F for 2025, “Group Subsidiaries and Holdings” (printed pages F-61 to F-65): https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm (filed 2026-02-24; retrieved 2026-10-15)
- BODACC notices for RCS 558 201 075, including the draft-merger notice of 2021-07-01 and the capital notice of 2021-10-12: https://bodacc-datadila.opendatasoft.com/explore/dataset/annonces-commerciales/ (retrieved 2026-10-15)
- Recherche d’entreprises API, ASTRA ZENECA HOLDING FRANCE, SIREN 399324011 (closed 2021-08-31): https://recherche-entreprises.api.gouv.fr/search?q=399324011 (retrieved 2026-10-15)
- astrazeneca.fr legal notice (share capital): https://www.astrazeneca.fr/mentions-legales.html (retrieved 2026-10-15)
Data-provider feed — rows as supplied to Zavia for INPI (Institut National de la Propriété Industrielle), including entries the profile above does not cover. These rows are not a verbatim copy of the register: they have been found to duplicate the same person under different spellings and to keep a status of Active after an appointment ended. Where they disagree with the profile above, the profile is the checked version.
| Shareholder | Type | Holding | Source Document |
|---|---|---|---|
| Anne-Laure Dreno | 100% | INPI (Institut National de la Propriété Industrielle) |
Officers
5
Directors and officers of ASTRAZENECA
The latest BODACC notice for ASTRAZENECA (SIREN 558 201 075), published on 26 July 2026, lists two current corporate officers and one statutory auditor. The national company register (RNE), as served by the Recherche d’entreprises API on 15 October 2026, gives the same list:
- Auriane Cano-Chancel, Président (the legal representative of an SAS)
- Anne-Sylvie Lefebvre, Directeur général délégué (deputy managing director)
- KPMG S.A. (SIREN 775 726 417), commissaire aux comptes titulaire (statutory auditor). KPMG is a corporate appointee, not a natural person.
The 2026 notices do not give appointment dates for these offices. The dates below are BODACC publication dates, not effective dates. Earlier notices record former office-holders with dates. Françoise Bartoli was Président from 16 September 2010. Rachid Izzar was Président from 27 October 2017. Anne-Céline Barois was pharmacien responsable and Directeur général délégué from 28 July 2017.
The officer table supplied with this profile holds 5 of the 11 rows its provider reports. In that table, a former Président, a former deputy and the former auditor PricewaterhouseCoopers Audit are still shown as active. The current Président, the current Directeur général délégué and KPMG S.A. do not appear. One stored appointment date (7 April 2016 for Françoise Bartoli) contradicts the register’s 16 September 2010.
Recent officer changes
- Président: Anne-Laure Dreno is named as Président in BODACC notices from 10 August 2023 to 5 March 2026. Auriane Cano-Chancel is named from the notice of 10 April 2026 onward.
- Directeur général délégué: the notice of 9 January 2026 names Anne-Marie Marx. The notice of 5 March 2026 names Anne-Sylvie Lefebvre.
- Statutory auditor: PricewaterhouseCoopers Audit (in office from 13 September 2017) is replaced by KPMG S.A. in the notice of 26 July 2026.
Data availability
Availability: Current and historical, through BODACC and the RNE. French registers publish officers’ names, roles and month and year of birth. They do not publish nationality, so nationality is Not disclosed for all officers. The 2026 notices give no effective dates for the changes listed above.
Sources
- BODACC, notices for RCS 558 201 075 dated 2017-08-03, 2017-11-02, 2023-08-10, 2026-01-09, 2026-03-05, 2026-04-10 and 2026-07-26: https://bodacc-datadila.opendatasoft.com/explore/dataset/annonces-commerciales/ (retrieved 2026-10-15)
- Recherche d’entreprises API (RNE data, updated 2026-09-24): https://recherche-entreprises.api.gouv.fr/search?q=558201075 (retrieved 2026-10-15)
Data-provider feed — rows as supplied to Zavia for INPI (Institut National de la Propriété Industrielle), including entries the profile above does not cover. These rows are not a verbatim copy of the register: they have been found to duplicate the same person under different spellings and to keep a status of Active after an appointment ended. Where they disagree with the profile above, the profile is the checked version.
Group Structure
Group structure of ASTRAZENECA
ASTRAZENECA (SIREN 558 201 075) belongs to the AstraZeneca group. Its ultimate parent is AstraZeneca PLC, a public limited company registered in England and Wales under number 02723534. In its Annual Report on Form 20-F for 2025, AstraZeneca PLC lists “AstraZeneca SAS” among its wholly owned subsidiaries, with a 100% group interest at 31 December 2025. Under the note’s general rule, the holding is indirect, because no footnote marks it as directly held. The filing does not name the immediate parent, and no French public register does either. The immediate parent is therefore not disclosed.
The corporate tree supplied with this profile places this company directly under AstraZeneca PLC. That conflicts with the filing’s indirect holding. The tree also shows AstraZeneca Dunkerque Production and Amolyt Pharma as subsidiaries of this company. No filing reviewed supports either link. For AstraZeneca Dunkerque Production, a société en commandite simple, BODACC notices name AstraZeneca AB as its associé commandité (general partner). The 20-F lists both companies as 100%-owned group companies. They are treated below as fellow group companies, not as subsidiaries of ASTRAZENECA.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | United Kingdom | 02723534 | Ultimate parent | 100% group interest, held indirectly | Listed company | 31 Dec 2025 |
| Immediate parent | Not disclosed | Not disclosed | Immediate parent | Ownership percentage not disclosed | Not disclosed | 15 Oct 2026 |
| ASTRA ZENECA HOLDING FRANCE | France | SIREN 399 324 011 | Historical: absorbed by ASTRAZENECA by merger | Not applicable | Closed 31 Aug 2021 | 1 Jul 2021 (draft merger notice) |
| Alexion Pharma France SAS | France | SIREN 491 411 336 | Fellow group company (same ultimate parent) | 100% group interest | Active | 31 Dec 2025 |
| AstraZeneca Dunkerque Production SCS | France | SIREN 448 139 634 | Fellow group company (same ultimate parent) | 100% group interest | Active | 31 Dec 2025 |
| AstraZeneca Reims Production SAS | France | SIREN 889 765 681 | Fellow group company (same ultimate parent) | 100% group interest | Active | 31 Dec 2025 |
| Amolyt Pharma SAS | France | SIREN 803 919 729 | Fellow group company (same ultimate parent) | 100% group interest (ordinary and preference shares) | Active | 31 Dec 2025 |
Recent structural changes
- 2021: under a draft merger agreement of 25 June 2021, ASTRAZENECA absorbed ASTRA ZENECA HOLDING FRANCE. The net assets contributed were EUR 273,793,972. Sirene records the absorbed company as closed on 31 August 2021 (BODACC notice of 1 July 2021).
- 1 July 2022: a business (fonds) previously held at ASTRAZENECA’s Courbevoie address was sold to Alexion Pharma France, under a deed dated 27 June 2022 (BODACC notice of 10 July 2022).
Data availability
Availability: Partial. The ultimate parent and the 100% group interest are disclosed in AstraZeneca PLC’s statutory list of group undertakings. The intermediate holding companies and the immediate parent are not published. French registers do not publish SAS shareholders. The French register of beneficial owners has been closed to the public since 2022.
Sources
- AstraZeneca PLC, Annual Report on Form 20-F for 2025, “Group Subsidiaries and Holdings” (printed pages F-61 to F-65) and company information note: https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm (filed 2026-02-24; retrieved 2026-10-15)
- BODACC notices for RCS 558 201 075 (2021-07-01, 2022-07-10) and RCS 448 139 634 (2013-01-03): https://bodacc-datadila.opendatasoft.com/explore/dataset/annonces-commerciales/ (retrieved 2026-10-15)
- Recherche d’entreprises API, SIRENs 558201075, 399324011, 491411336, 448139634, 889765681 and 803919729: https://recherche-entreprises.api.gouv.fr/search?q=399324011 (retrieved 2026-10-15)
Data-provider feed — rows as supplied to Zavia for INPI (Institut National de la Propriété Industrielle), including entries the profile above does not cover. These rows are not a verbatim copy of the register: they have been found to duplicate the same person under different spellings and to keep a status of Active after an appointment ended. Where they disagree with the profile above, the profile is the checked version.
ASTRAZENECA PLC
United Kingdom
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does ASTRAZENECA do?
ASTRAZENECA (SIREN 558 201 075) is a French SAS registered at the RCS of Nanterre, based in Courbevoie, whose registered activity is the manufacture and sale of pharmaceutical products (NAF 21.20Z).
Who owns ASTRAZENECA?
French registers do not publish SAS shareholders. AstraZeneca PLC's 2025 Form 20-F lists AstraZeneca SAS as 100% owned by the group, held indirectly; the immediate shareholder is not disclosed.
Who is ASTRAZENECA's UBO (Ultimate Beneficial Owner)?
No natural person is publicly identified as a beneficial owner of ASTRAZENECA SAS. It is 100% indirectly owned by the listed AstraZeneca PLC, and the French beneficial-ownership register has been closed to the public since 2022.
What is ASTRAZENECA's company registration number?
ASTRAZENECA's registration number is 55820107500071, filed with INPI (Institut National de la Propriété Industrielle) in France. Its current status on the register is active.
Is ASTRAZENECA still an active company?
ASTRAZENECA's status on INPI (Institut National de la Propriété Industrielle) is listed as active.
What is ASTRAZENECA's registered address?
The registered address on file for ASTRAZENECA is COURBEVOIE, France.
What legal structure is ASTRAZENECA registered as?
ASTRAZENECA is registered as a Public Limited Company in France.
What is ASTRAZENECA's revenue?
In its own (non-consolidated) accounts for 2025, ASTRAZENECA SAS reported revenue of EUR 1,211.5 million and net profit of EUR 25.2 million (2024: EUR 999.2 million and EUR 37.8 million). AstraZeneca group figures are not this company's figures.
Is ASTRAZENECA listed on a stock exchange?
ASTRAZENECA SAS is not itself listed. Its ultimate parent, AstraZeneca PLC (England and Wales, no. 02723534), is a listed company trading under the symbol AZN.
Who are the officers/directors of ASTRAZENECA?
According to the BODACC notice of 26 July 2026 and the RNE, the Président is Auriane Cano-Chancel and the Directeur général délégué is Anne-Sylvie Lefebvre. KPMG S.A. is the statutory auditor.
Does ASTRAZENECA have a parent company or subsidiaries?
ASTRAZENECA SAS is an indirectly held, wholly owned company of AstraZeneca PLC (100% group interest at 31 December 2025). In 2021 it absorbed ASTRA ZENECA HOLDING FRANCE by merger.
Can Zavia monitor changes to ASTRAZENECA's ownership over time?
This profile reflects a point-in-time snapshot from INPI (Institut National de la Propriété Industrielle). Zavia's monitoring API can track changes to ASTRAZENECA's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access ASTRAZENECA's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including France, so records like ASTRAZENECA's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from INPI (Institut National de la Propriété Industrielle) and was last synced on 8 October 2026.